bioRxivNeurosciencePreprint
Cognitive impairment and progressive neuroinflammation in mucopolysaccharidosis IIIA mice expressing the R245H Sgsh variant
Adeline A. LauiD, Paul J. TrimiD, Helen BeardiD, Ashleigh Lake, Barbara M. KingiD, Marten F. SneliD, Kim M. HemsleyiD
Abstract
Mucopolysaccharidosis (MPS) type IIIA (Sanfilippo syndrome) is an inherited childhood-onset dementia caused by insufficient SGSH enzymatic activity and subsequent accumulation of partially degraded heparan sulfate glycosaminoglycans. One of the most prevalent mutations is the Arg245His variant, representing up to 58% of mutations in some populations. Whilst other mouse models exist, none exhibit the mutations seen in humans, thus their amenability to testing of therapeutics such as pharmacological chaperones, which are often mutation-dependent, is limited. We have used CRISPR/Cas 9 gene editing to generate the first SgshR245H knock-in mouse model of MPS IIIA, which subsequently underwent extensive phenotyping. SgshR245H mouse brain exhibited progressive accumulation of heparan sulfate, endo/lysosomal system expansion and elevated levels of GFAP-reactive astroglial staining and activated microglia. Significant perturbation in several novel lipid species was observed in the CA1 region of the hippocampus using Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry Imaging. Spatial memory deficits were apparent in the Morris Water Maze probe and Y-maze tests, and Elevated Plus Maze exploration revealed reduced anxiety-like behaviours. SgshR245H MPS IIIA mice recapitulate key characteristics of the human disorder and represent a useful tool for studying disease pathogenesis and evaluating novel therapeutic approaches. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/691757v2_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@17ee5bforg.highwire.dtl.DTLVardef@1d7e23org.highwire.dtl.DTLVardef@445800org.highwire.dtl.DTLVardef@ed7dad_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oral Glucosamine Ameliorates Aggravated Neurological Phenotype in Mucopolysaccharidosis III Type C Mouse Model Expressing Misfolded HGSNAT Variant
X. Pan, M. Taherzadeh, … A. V. Pshezhetsky·bioRxiv·Aug 26, 2021
- Zebrafish models of Mucopolysaccharidosis IIIA, IIIB, and IIIC show hyperactivity, neuroinflammation and changes in oligodendrocyte cell state
Ewan Gerken, Syahida Ahmad, … Michael T. Lardelli·bioRxiv·Aug 2, 2023
- Systems-level investigation of mucopolysaccharidosis IIIA identifies deficient synaptic activity as a key driver of disease progression
Alon M. Douek, Adrian Salavaty, … Jan Kaslin·bioRxiv·Oct 3, 2022
- Heterologous HSPC transplantation rescues neuroinflammation and ameliorates peripheral manifestations in the mouse model of lysosomal transmembrane enzyme deficiency, MPS IIIC.
Xuefang Pan, Antoine Caillon, … Alexey V. Pshezhetsky·CellsPeer-reviewed·May 20, 2024
- Synthetic analogue of adrenocorticotropic hormone, ACTH(4-7)PGP delays neurological manifestations in diseases of mucopolysaccharidosis III spectrum by reducing neuroinflammation and rescuing neurotransmission, synaptogenesis, and axonal demyelination
Travis Mooree, Patricia Dubot, … Alexey V. Pshezhetsky·bioRxiv·Feb 24, 2026
- Severe Central Nervous System Demyelination in Sanfilippo Disease
Mahsa Taherzadeh, Erjun Zhang, … Alexey V. Pshezhetsky·Frontiers in Molecular NeurosciencePeer-reviewed·Dec 12, 2023